Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1999 Jul;80(9):1392–1399. doi: 10.1038/sj.bjc.6690534

Prognostic factors in patients progressing after cisplatin-based chemotherapy for malignant non-seminomatous germ cell tumours

S D Fosså 1, S P Stenning 2, A Gerl 3, A Horwich 4, P I Clark 5, P M Wilkinson 6, W G Jones 7, M V Williams 8, R T Oliver 9, E S Newlands 10, G M Mead 11, M H Cullen 12, S B Kaye 13, G J S Rustin 14, P A Cook 2
PMCID: PMC2363071  PMID: 10424741

Abstract

The aim of this study was to define prognostic parameters for survival in patients with malignant germ cell tumours progressing after platinum-based induction chemotherapy with or without surgery. A total of 164 progressing patients (testicular: 83%, extragonadal: 17%) were identified out of 795 patients treated with platinum-based induction chemotherapy for metastatic germ cell malignancy with or without surgery. ‘Progressive disease’ included patients who had progressed after a previous partial or complete remission as well as patients who failed primary therapy. Salvage chemotherapy consisted of ‘conventional’ platinum-based chemotherapy. Prognostic factors for survival were assessed by uni- and multivariate analyses. The resulting prognostic model was validated in an independent data set of 66 similar patients. For all 164 patients the median time from start of induction chemotherapy to progression was 10 months (range: 0–99). Thirty-eight (23%) patients relapsed after 2 years. The 5-year survival rate for all progressing patients was 30% (95% confidence interval 23–38%). In the univariate analysis the following factors most importantly predicted a poor prognosis: progression-free interval < 2 years: initial poor prognosis category (MRC criteria), < CR to induction chemotherapy, initial treatment early in the 1980s and treatment given at a ‘small’ centre. Three prognostic factors remained in the multivariate analysis: progression-free interval, response to induction treatment and the level of serum human chronic gonadotrophin (hCG) and alpha fetoprotein (AFP) at relapse. One hundred and twenty-four patients could be classified on the basis of these characteristics, Those patients with progression-free interval < 2 years, < CR to induction chemotherapy and high markers at relapse (AFP >100 kU l−1 or hCG >100 IU l−1) formed a poor prognosis group of 30 patients, none of whom survived after 3 years. Patients with at most two of these three risk factors formed a good prognosis group of 94 patients (76%) with a 47% (37–56%) 5-year survival. Thirty-eight patients from the good prognosis group with a progression-free interval of >2 years had a 2-year survival of 74% (60–88%) and 5-year survival of 61%. These prognostic groups were validated in the independent data set, in which 5-year survival rates in the good and poor risk groups were 51% and 0% respectively. One-third of patients progressing during or after platinum-based induction chemotherapy for metastatic germ cell malignancy may be cured by repeated ‘conventional’ platinum-based chemotherapy. Good prognosis parameters are: progression-free interval of > 2 years, CR to induction treatment and normal or low serum markers at relapse (hCG < 100 IU l−1 and AFP < 100 kU l−1). The results of high-dose salvage chemotherapy should be interpreted on the background of these prognostic factors. © 1999 Cancer Research Campaign

Keywords: germ cell malignancy, relapse, cisplatin-based chemotherapy, survival

Full Text

The Full Text of this article is available as a PDF (87.6 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Baniel J., Foster R. S., Gonin R., Messemer J. E., Donohue J. P., Einhorn L. H. Late relapse of testicular cancer. J Clin Oncol. 1995 May;13(5):1170–1176. doi: 10.1200/JCO.1995.13.5.1170. [DOI] [PubMed] [Google Scholar]
  2. Beyer J., Kramar A., Mandanas R., Linkesch W., Greinix A., Droz J. P., Pico J. L., Diehl A., Bokemeyer C., Schmoll H. J. High-dose chemotherapy as salvage treatment in germ cell tumors: a multivariate analysis of prognostic variables. J Clin Oncol. 1996 Oct;14(10):2638–2645. doi: 10.1200/JCO.1996.14.10.2638. [DOI] [PubMed] [Google Scholar]
  3. Broun E. R., Nichols C. R., Kneebone P., Williams S. D., Loehrer P. J., Einhorn L. H., Tricot G. J. Long-term outcome of patients with relapsed and refractory germ cell tumors treated with high-dose chemotherapy and autologous bone marrow rescue. Ann Intern Med. 1992 Jul 15;117(2):124–128. doi: 10.7326/0003-4819-117-2-124. [DOI] [PubMed] [Google Scholar]
  4. Cassidy J., Lewis C. R., Kaye S. B., Kirk D. The changing role of surgery in metastatic non-seminomatous germ cell tumour. Br J Cancer. 1992 Jan;65(1):127–129. doi: 10.1038/bjc.1992.24. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Gerl A., Clemm C., Schmeller N., Hartenstein R., Lamerz R., Wilmanns W. Prognosis after salvage treatment for unselected male patients with germ cell tumours. Br J Cancer. 1995 Oct;72(4):1026–1032. doi: 10.1038/bjc.1995.456. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Horwich A., Sleijfer D. T., Fosså S. D., Kaye S. B., Oliver R. T., Cullen M. H., Mead G. M., de Wit R., de Mulder P. H., Dearnaley D. P. Randomized trial of bleomycin, etoposide, and cisplatin compared with bleomycin, etoposide, and carboplatin in good-prognosis metastatic nonseminomatous germ cell cancer: a Multiinstitutional Medical Research Council/European Organization for Research and Treatment of Cancer Trial. J Clin Oncol. 1997 May;15(5):1844–1852. doi: 10.1200/JCO.1997.15.5.1844. [DOI] [PubMed] [Google Scholar]
  7. Josefsen D., Ous S., Høie J., Stenwig A. E., Fosså S. D. Salvage treatment in male patients with germ cell tumours. Br J Cancer. 1993 Mar;67(3):568–572. doi: 10.1038/bjc.1993.104. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Lederman G. S., Garnick M. B. Possible benefit of doxorubicin treatment in patients with refractory germ cell cancer. Cancer. 1986 Dec 1;58(11):2393–2398. doi: 10.1002/1097-0142(19861201)58:11<2393::aid-cncr2820581107>3.0.co;2-i. [DOI] [PubMed] [Google Scholar]
  9. Ledermann J. A., Holden L., Newlands E. S., Begent R. H., Rustin G. J., Bagshawe K. D., Brampton M. The long-term outcome of patients who relapse after chemotherapy for non-seminomatous germ cell tumours. Br J Urol. 1994 Aug;74(2):225–230. doi: 10.1111/j.1464-410x.1994.tb16591.x. [DOI] [PubMed] [Google Scholar]
  10. Levi J. A., Thomson D., Harvey V., Gill G., Raghavan D., Tattersall M., Snyder R., Burns I., Sandeman T., Byrne M. Effective salvage chemotherapy with etoposide, dactinomycin, and methotrexate in refractory germ cell cancer. Australasian Germ Cell Trial Group. J Clin Oncol. 1990 Jan;8(1):27–32. doi: 10.1200/JCO.1990.8.1.27. [DOI] [PubMed] [Google Scholar]
  11. Loehrer P. J., Sr, Einhorn L. H., Williams S. D. VP-16 plus ifosfamide plus cisplatin as salvage therapy in refractory germ cell cancer. J Clin Oncol. 1986 Apr;4(4):528–536. doi: 10.1200/JCO.1986.4.4.528. [DOI] [PubMed] [Google Scholar]
  12. Loehrer P. J., Sr, Gonin R., Nichols C. R., Weathers T., Einhorn L. H. Vinblastine plus ifosfamide plus cisplatin as initial salvage therapy in recurrent germ cell tumor. J Clin Oncol. 1998 Jul;16(7):2500–2504. doi: 10.1200/JCO.1998.16.7.2500. [DOI] [PubMed] [Google Scholar]
  13. Margolin K., Doroshow J. H., Ahn C., Hamasaki V., Leong L., Morgan R., Raschko J., Shibata S., Somlo G., Tetef M. Treatment of germ cell cancer with two cycles of high-dose ifosfamide, carboplatin, and etoposide with autologous stem-cell support. J Clin Oncol. 1996 Oct;14(10):2631–2637. doi: 10.1200/JCO.1996.14.10.2631. [DOI] [PubMed] [Google Scholar]
  14. McCaffrey J. A., Mazumdar M., Bajorin D. F., Bosl G. J., Vlamis V., Motzer R. J. Ifosfamide- and cisplatin-containing chemotherapy as first-line salvage therapy in germ cell tumors: response and survival. J Clin Oncol. 1997 Jul;15(7):2559–2563. doi: 10.1200/JCO.1997.15.7.2559. [DOI] [PubMed] [Google Scholar]
  15. Mead G. M., Stenning S. P., Parkinson M. C., Horwich A., Fossa S. D., Wilkinson P. M., Kaye S. B., Newlands E. S., Cook P. A. The Second Medical Research Council study of prognostic factors in nonseminomatous germ cell tumors. Medical Research Council Testicular Tumour Working Party. J Clin Oncol. 1992 Jan;10(1):85–94. doi: 10.1200/JCO.1992.10.1.85. [DOI] [PubMed] [Google Scholar]
  16. Motzer R. J., Bajorin D. F., Schwartz L. H., Hutter H. S., Bosl G. J., Scher H. I., Lyn P., Fischer P. Phase II trial of paclitaxel shows antitumor activity in patients with previously treated germ cell tumors. J Clin Oncol. 1994 Nov;12(11):2277–2283. doi: 10.1200/JCO.1994.12.11.2277. [DOI] [PubMed] [Google Scholar]
  17. Motzer R. J., Geller N. L., Tan C. C., Herr H., Morse M., Fair W., Sheinfeld J., Sogani P., Russo P., Bosl G. J. Salvage chemotherapy for patients with germ cell tumors. The Memorial Sloan-Kettering Cancer Center experience (1979-1989). Cancer. 1991 Mar 1;67(5):1305–1310. doi: 10.1002/1097-0142(19910301)67:5<1305::aid-cncr2820670506>3.0.co;2-j. [DOI] [PubMed] [Google Scholar]
  18. Siegert W., Beyer J., Strohscheer I., Baurmann H., Oettle H., Zingsem J., Zimmermann R., Bokemeyer C., Schmoll H. J., Huhn D. High-dose treatment with carboplatin, etoposide, and ifosfamide followed by autologous stem-cell transplantation in relapsed or refractory germ cell cancer: a phase I/II study. The German Testicular Cancer Cooperative Study Group. J Clin Oncol. 1994 Jun;12(6):1223–1231. doi: 10.1200/JCO.1994.12.6.1223. [DOI] [PubMed] [Google Scholar]
  19. Williams S. D., Birch R., Einhorn L. H., Irwin L., Greco F. A., Loehrer P. J. Treatment of disseminated germ-cell tumors with cisplatin, bleomycin, and either vinblastine or etoposide. N Engl J Med. 1987 Jun 4;316(23):1435–1440. doi: 10.1056/NEJM198706043162302. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES